PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 04:12:27 2024-07-16 am EDT | ||
| 1.52 EUR | -26.57% |
|
| Current month | -61.95% | ||
| 1 month | -75.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 1.52 | -26.57% |
| 24-07-15 | 2.07 | -5.05% |
| 24-07-12 | 2.18 | -44.25% |
| 24-07-11 | 3.91 | +26.95% |
| 24-07-10 | 3.08 | -23.19% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 04:12 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KJM |
| ISIN | DE000VD0KJM4 |
| Date issued | 2024-02-19 |
| Strike | 969.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.14 € |
|---|---|
| Lowest since issue | 0.87 € |
| Spread | 0.36 € |
| Spread % | 18.27% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Certificates
- Certificat
